Myriad Genetics (MYGN) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1 year target prices for Myriad Genetics' stock. Their MYGN share price forecasts range from $17.00 to $28.00. On average, they predict the company's share price to reach $24.20 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

Myriad Genetics' stock was trading at $14.51 at the start of the year. Since then, MYGN shares have increased by 14.5% and is now trading at $16.61.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our MYGN earnings forecast.

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The business earned $183.50 million during the quarter, compared to the consensus estimate of $187.16 million. Myriad Genetics had a negative trailing twelve-month return on equity of 9.43% and a negative net margin of 35.51%. The company's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) EPS.

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY).

Myriad Genetics updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus earnings per share estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $742.12 million.

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.23%), Camber Capital Management LP (8.10%), State Street Corp (5.77%), Earnest Partners LLC (3.99%), Dimensional Fund Advisors LP (3.27%) and Artisan Partners Limited Partnership (3.10%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYGN stock can currently be purchased for approximately $16.61.

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.36 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

The company employs 2,600 workers across the globe.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.